Oragenics Inc

Name: Oragenics Inc standardized financial statements, quarterly
Creator: Listed

OGENNYSECIK 1174940HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2023

Operating income−$2.6m, Q2 FY2026

Net income−$2.5m, Q2 FY2026

Oragenics Inc, income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Cost of revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$m	0.8	11.0	0.7	0.9	0.9	1.7	0.3	0.4	0.9	0.7	0.6	1.2
Selling, general and administrative	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Operating income	$m	(2.1)	(12.8)	(2.5)	(2.3)	(2.4)	(3.4)	(2.0)	(1.7)	(3.1)	(2.5)	(2.3)	(2.6)
Interest expense	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.0
Income tax	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	(0.0)	(0.0)
Net income	$m	(2.0)	(12.7)	(2.5)	(2.3)	(2.5)	(3.3)	(2.2)	(2.3)	(3.1)	(2.3)	(2.2)	(2.5)
Diluted EPS	$ per share	(0.85)	not reported	(0.70)	(15.27)	(11.32)	not reported	(3.65)	(3.10)	(1.96)	not reported	(0.51)	(0.57)
Basic EPS	$ per share	(0.85)	not reported	(0.70)	(15.27)	(11.32)	not reported	(3.65)	(3.10)	(1.96)	not reported	(0.51)	(0.57)

Balance sheet

Cash and equivalents$3.9m, Q2 FY2026

Shareholders' equity$3.7m, Q2 FY2026

Oragenics Inc, balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	5.8	3.5	2.1	1.3	3.1	0.9	3.4	2.0	11.4	4.4	6.1	3.9
Current assets	$m	7.8	3.9	2.4	1.6	4.1	1.5	3.9	2.1	12.7	10.1	7.5	5.5
Total assets	$m	7.9	5.0	3.5	2.7	5.2	1.5	3.9	2.1	12.7	10.1	7.5	5.5
Current liabilities	$m	1.4	1.8	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Total liabilities	$m	not reported	1.8	0.9	1.4	2.1	1.7	3.7	4.3	2.9	1.8	1.3	1.8
Shareholders' equity	$m	6.5	3.2	2.6	1.3	3.1	(0.2)	0.1	(2.1)	9.8	8.3	6.2	3.7

Cash flow

Operating cash flow−$2.2m, Q2 FY2026

Oragenics Inc, cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(1,503)	(1,103)	(3,064)	(1,545)	(1,970)	(2,018)	(2,112)	(1,314)	(2,985)	(2,835)	(2,201)	(2,187)
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)4.43m, Q2 FY2026

Oragenics Inc, shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	1,946	2,205	2,025	2,356	3,496	151	218	607	732	1,561	4,301	4,429

Shares outstanding: 4.51m at Aug 12, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. Listed shows no prices and gives no investment advice.